Immunitybio, Inc.

This early-stage trial tests a new combination of drugs given before surgery for people with pancreatic cancer that is either hard to remove or too advanced for immediate surgery. The goal is to see if the treatment is safe and can shrink tumors enough to allow successful surgery…

This study tests two experimental treatments for people with intermediate-risk non-muscle invasive bladder cancer. The goal is to see if a drug called N-803, given with either BCG or gemcitabine directly into the bladder, can eliminate tumors without needing surgery. About 20 adu…

This study tests an experimental drug (NAI) added to usual care for critically ill adults with sepsis who have persistently low levels of a key immune cell (lymphocytes). The goal is to see if the drug can help the immune system recover and lower the risk of death within 28 days.…

This study tests a new drug combination for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The treatment uses three immune-based drugs (CD19 t-haNK, NAI, and rituximab) without chemotherapy. About 20 adults …

This study tests whether adding an experimental drug (nogapendekin alfa inbakicept) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 494 adults with stage IV lung cancer who have no…